FDA green lights obe-cel in relapsed or refractory B-cell ALL
The US Food and Drug Administration (FDA) has approved obecabtagene autoleucel (obe-cel) in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Leukemia
Leukemia
Chronic Myeloid Leukemia
News
Dasatinib, asciminib combo shows ‘promise’ for upfront treatment of Ph+ ALL
Dasatinib has shown efficacy in treating patients with Philadelphia chromosome-positive (Ph+) acute leukemia, though some patients develop resistance. The authors of a phase